Kumovis GmbH

Kumovis GmbH specializes in 3D printing technology for medical applications, focusing on the production of customized implants and instruments using high-performance polymers to meet the specific needs of healthcare providers. Kumovis GmbH, founded in 2017 in Munich, Germany, develops advanced 3D printing solutions tailored for the medical sector. The company was co-founded by Alexander Henhammer, Miriam Haerst, Sebastian Pammer, Stefan Fischer, and Stefan Leonhardt. In February 2022, Kumovis was acquired by 3D Systems, Inc.

, a significant development in its operational strategy. The acquisition is anticipated to be completed by April 2022. Kumovis GmbH's flagship product is the EXT 220 MED, a sophisticated 3D printer designed for manufacturing medical implants and instruments from high-performance polymers like PEEK and Radel® PPSU. This printer utilizes filament-based extrusion technology to create patient-specific medical devices, addressing the rising demand for individualized surgical solutions within healthcare.

The EXT 220 MED incorporates essential features such as a clean room environment and temperature control systems to maintain high-quality manufacturing standards. The target audience includes hospitals, medical device manufacturers, and specialized healthcare providers in North America, Europe, and Asia. Kumovis GmbH's revenue model is based on the sale of high-tech medical 3D printers and associated materials, including proprietary polymers designed for medical use. The company engages in direct sales to healthcare institutions and medical device manufacturers, facilitating the production of customized medical solutions.

Collaborations with hospitals and research institutions support the implementation of the EXT 220 MED system in clinical settings. Pricing structures are tailored to meet the customization needs of clients, often complemented by service agreements and maintenance contracts. A hallmark product made possible by the EXT 220 MED is the VSP® PEEK Cranial Implant, addressing critical surgical needs in neurotrauma and craniofacial applications. With recent funding of EUR 3.

60 mn raised in its Series A round on February 23, 2022, Kumovis GmbH plans to leverage this investment to enhance its product development and expand its market reach. The company is focusing on launching new iterations of its 3D printing technology designed for broader medical applications and intends to penetrate additional geographic markets, particularly in Asia and North America, by 2023.